Silence therapeutics presents promising phase 1 data in polycythemia vera patients at the american society of hematology (ash) annual meeting

London--(business wire)---- $sln #senseofsilence--silence therapeutics plc (“silence” or the “company”) (nasdaq: sln), a global clinical-stage company developing novel sirna (short interfering rna) therapies, today announced additional results from the phase 1 open label portion of the sanreco study of divesiran, a sirna targeting tmprss6, in patients with polycythemia vera (pv) were presented at the american society of hematology (ash) annual meeting being held in san diego, california. “additional divesiran data pres.
ASH Ratings Summary
ASH Quant Ranking